Cytotoxic effect of combined treatment with Ukrain and methotrexate on kidney cells of green monkey

• Autorzy: Izdebska M. , Piatkowska-Chmiel I. , Jagiello-Wojtowicz E.
• Języki publikacji: EN

Abstrakty

EN

In in vitro study on green monkey kidney (GMK) cell culture, the cytotoxicity of Ukrain, methotrexate (MTX), and their combination was investigated. The effect of these drugs and their combination on viability (MTT test) and apoptosis of the cells was assessed. The IC₁₀ and IC₅₀ values for Ukrain and MTX were also indicated. After 24 h of incubation of GMK cells with Ukrain, IC₁₀ amounted to 84.6 µmol/L and IC₅₀ was 256.3 µmol/L, while MTX IC₁₀ amounted to 7.18 µmol/L and IC₅₀ was 154.8 µmol/l. After 24 h of simultaneous incubation of GMK cells with 50 µmol/L of Ukrain and 5.5 µmol/L of MTX, 15.33 % of cytotoxicity of the drugs in LDH test was found. The most significant increase in the cytotoxicity (42.10 %) was noted after 24 h incubation of GMK cells with 150 µmol/L of Ukrain and 5.5 µmol/L of MTX. Likewise, in the MTT assay the greatest decrease in the cells viability was found after incubation with 150 µmol/L of Ukrain and 5.5 µmol/L of MTX. The evaluation of apoptosis also indicated the adverse effect of combined application of both drugs on GMK cells.

• Wydawca: -
• Czasopismo: Bulletin of the Veterinary Institute in Puławy
• Rocznik: 2012
• Tom: 56
• Numer: 1
• Opis fizyczny: p.57-62,fig.,ref.

Twórcy

autor

Izdebska M.

• Department of Toxicology, Medical University of Lublin, 20-093 Lublin, Poland

autor

Piatkowska-Chmiel I.

autor

Jagiello-Wojtowicz E.

Bibliografia

• 1. Aschhoff B.: Retrospective study of Ukrain treatment in 203 patients with advanced-stage tumors. Drugs Exp Clin Res 2000, 26, 249-252.
• 2. Bangert C.A., Costner M.I.: Methotrexate in dermatology. Dermatol Ther 2007, 20, 216-228.
• 3. Blower P., de Wit R., Goodin S., Aapro M.: Drug - drug interactions on oncology : Why are they important and can they be minimized? Crit Rev Oncol Hematol 2005, 55, 117-142.
• 4. Chatham W.W., Morgan S.L., Alarcón G.S.: Renal failure: a risk factor for methotrexate toxicity. Arthritis Rheum 2000, 43, 1185-1186.
• 5. Decker S., Winkelmann W., Nies B., van Valen F.: Cytotoxic effect of methotrexate and its solvent on osteosarcoma cells in vitro. J Bone Joint Surg 1999, 81- B, 545-551.
• 6. Genestier L., Paillot R., Fournel S., Ferraro C., Miossec P., Revillard J.P.: Immunosuppressive properties of methotrexate: Apoptosis and clonal deletion of activated peripheral T cells. J Clin Invest 1998, 102, 247-257.
• 7. Green M.R., Chamberlain M.C.: Renal dysfunction during and after high-dose methotrexate. Cancer Chemother Pharmacol 2009, 63, 599-604.
• 8. Habermehl D., Kammerer B., Handrick R., Eldh T., Gruber C., Cordes N., Daniel P.T., Plasswilm L., Bamberg M., Belka C., Jendrossek V.: Proapoptotic activity of Ukrain is based on Chelidonium majus L. alkaloids and mediated via a mitochondrial death pathway. BMC Cancer 2006, 6, 14-36.
• 9. Hattangadi D.K., DeMasters G.A., Walker T.D., Jones K.R., Di X., Newsham I.F., Gewirtz D.A.: Influence of p53 and caspase 3 activity on cell death and senescence in response to methotrexate in the breast tumor cell. Biochem Pharmacol 2004, 68, 1699-1708.
• 10. Hohenwarter O.: Selective inhibition of in vitro cell growth by the anti-tumor drug Ukrain. Drugs Exp Clin Res 1992, 18, 1-4.
• 11. Jagiełło-Wojtowicz E., Kleinrok Z., Urbanska E.M.: Ukrain (NSC631570) in experimental and clinical studies: a review. Drugs Exp Clin Res 1998, 24, 213- 219.
• 12. Kang M.H., Harutyunyan N., Hall C.P., Papa R.A., Lock R.B.: Methotrexate and aminopterin exhibit similar in vitro and in vivo preclinical activity against acute lymphoblastic leukaemia and lymphoma. Br J Haematol 2009, 145, 389-393.
• 13. Kimura E., Nishimura K., Sakata K., Opa S., Kashiwagi K., Igarashi K.: Methotrexate differentially affects growth of suspension and adherent cells. Int J Biochem Cell Biol 2004, 36, 814-825.
• 14. Lanvers-Kaminsky C., Nolting D.M., Köster J., Schröder A., Sandkötter A., Boos J.: In vitro toxicity of Ukrain against human Ewing tumor cell lines. Anticancer Drugs 2006. 17, 1025-1030.
• 15. Liepins A., Nowicky J.W., Bustamante J.O., Lam E.: Induction of bimodal programmed cell death in malignant cells by the derivative Ukrain (NSC-631570). Drugs Exp Clin Res 1996, 22, 73-79.
• 16. Lohninger A., Hamler F.: Chelidonium majus L. (Ukrain) in the treatment of cancer patients. Drugs Exp Clin Res Drugs 1992, 18, 73-77.
• 17. Nowicky J.W., Hiesmayr W., Liepins A.: Influence of Ukrain on DNA, RNA and protein synthesis in malignant cells. Drugs Exp Clin Res 1996, 22, 81-91.
• 18. Nowicky J.W., Manolakis G., Meijer D., Vatanasapt V., Brzosko W.T.: Ukrain both as an anticancer and immunoregulatory agent. Drugs Exp Clin Res 1992, 18, 51-54.
• 19. Nowicky J.W., Nowicky W., Liepins A.: Cytostatic and cytotoxic effects of Ukrain on malignant cells. J Chemother 1993, 5, 797-780.
• 20. Panzer A., Hamel E., Joubert A.M., Bianchi P.C., Seegers J.C.: UkrainTM a semisynthetic Chelidonium majus alkaloid derivative, acts by inhibition of tubulin polymerization in normal and malignant cell lines. Cancer Lett 2000, 160, 149-157.
• 21. Roublevskaia I.N., Haake A.R., Ludlow J.W., Polevoda B.V.: Induced apoptosis in human prostate cancer cell line LNCaP by Ukrain. Drugs Exp Clin Res 2000, 26, 141-147.
• 22. Strang A., Pullar T.: Methotrexate toxicity induced by acute renal failure. J R Soc Med 2004, 97, 536-537.
• 23. Świerkot J., Szechiński J.: Methotrexate in rheumatoid arthritis. Pharmacol Rep 2006, 58, 473-492.
• 24. Tian H., Cronstein B.N.: Understanding the mechanisms of action of methotrexate. Bull NYU Hosp Jt Dis 2007, 65, 168-173.
• 25. Twentyman P.R., Luscombe M.: A study of some variables in a tetrazolium dye (MTT) based assav for cell growth and chemosensitivitx. Br J Cancer 1987, 56, 279- 285.
• 26. Uglyanitsa K.N., Nefyodov L.I., Doroshenko Y.M., Nowicky J.W., Volchek L.V., Brzosko W.J., Hodysh Y.J.: Ukrain: A novel antitumor drug. Drugs Exp Clin Res 2000, 26, 341-356.